DK2717891T3 - Bixa Orellana-sammensætning til behandling af makulær degeneration - Google Patents

Bixa Orellana-sammensætning til behandling af makulær degeneration Download PDF

Info

Publication number
DK2717891T3
DK2717891T3 DK12728639.1T DK12728639T DK2717891T3 DK 2717891 T3 DK2717891 T3 DK 2717891T3 DK 12728639 T DK12728639 T DK 12728639T DK 2717891 T3 DK2717891 T3 DK 2717891T3
Authority
DK
Denmark
Prior art keywords
composition
extract
composition according
treatment
bixa orellana
Prior art date
Application number
DK12728639.1T
Other languages
English (en)
Inventor
Stanislas Veillet
René LAFONT
Valérie Fontaine
José-Alain Sahel
Original Assignee
Biophytis
Université Pierre Et Marie Curie (Paris 6)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biophytis, Université Pierre Et Marie Curie (Paris 6) filed Critical Biophytis
Application granted granted Critical
Publication of DK2717891T3 publication Critical patent/DK2717891T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (9)

1. Sammensætning omfattende en ekstrakt af frø af Bixa Orellana til fotobeskyttelse af cellerne i det retinale pigmentepitel hos et pattedyr.
2. Sammensætning ifølge krav 1, til anvendelse i behandlingen af aldersrelateret maculadegeneration (AMD) hos et pattedyr.
3. Sammensætning ifølge krav 1, til anvendelse i behandlingen af Stargardts syndrom og/eller retinitis pigmentosa.
4. Sammensætning ifølge krav 1, til forebyggelse af beskadigelse af nethinden, som kunne være forårsaget af udsættelse for blåt lys med en bølgelængde på mellem 435 og 490 nm.
5. Sammensætning ifølge et af kravene 1 til 4, omfattende en bærer, som er acceptabel til at blive indtaget eller injiceret i øjet eller injiceret i blodet.
6. Sammensætning ifølge et af kravene 1 til 5, som et medikament eller et kosttilskud eller et næringsmiddel.
7. Sammensætning ifølge et af kravene 1 til 6, yderligere omfattende et gallussyrederivat og/eller en forbindelse af familien af anthocyanidiner.
8. Sammensætning ifølge krav 7, kendetegnet ved at gallussyrederivatet er ellaginsyre.
9. Sammensætning ifølge et af kravene 7 eller 8, kendetegnet ved at forbindelsen fra familien af anthocyanidiner er cyanidin.
DK12728639.1T 2011-05-13 2012-05-14 Bixa Orellana-sammensætning til behandling af makulær degeneration DK2717891T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1154172A FR2975008B1 (fr) 2011-05-13 2011-05-13 Utilisation de composes et composition pour le traitement de la degenerescence maculaire liee a l'age (dmla)
PCT/FR2012/000193 WO2012156600A1 (fr) 2011-05-13 2012-05-14 Composition de bixa orellana pour le traitement de la dégénérescence maculaire

Publications (1)

Publication Number Publication Date
DK2717891T3 true DK2717891T3 (da) 2017-01-09

Family

ID=46321067

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12728639.1T DK2717891T3 (da) 2011-05-13 2012-05-14 Bixa Orellana-sammensætning til behandling af makulær degeneration

Country Status (12)

Country Link
US (2) US20140322371A1 (da)
EP (1) EP2717891B1 (da)
JP (2) JP6421306B2 (da)
BR (1) BR112013029318A2 (da)
DK (1) DK2717891T3 (da)
ES (1) ES2609604T3 (da)
FR (2) FR2975008B1 (da)
HR (1) HRP20161718T1 (da)
HU (1) HUE031161T2 (da)
PL (1) PL2717891T3 (da)
PT (1) PT2717891T (da)
WO (1) WO2012156600A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2822898C (en) 2010-12-23 2021-01-05 Amazentis Sa Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders
CN104666920A (zh) * 2015-03-18 2015-06-03 莆田市山海天农业发展有限公司 一种治疗肝肾阴虚型视网膜色素变性的中药组合物
FR3035589B1 (fr) 2015-04-30 2019-12-13 Biophytis Composition pour la protection des cellules de l'epithelium pigmentaire retinien
FR3036620B1 (fr) * 2015-05-27 2017-09-01 Inst Biophytis Utilisation de 3-desoxyanthocyanidines pour le traitement de maladies oculaires
IT201700004599A1 (it) * 2017-01-17 2018-07-17 Safenat S R L “Composizioni a base di principi attivi di origine vegetale con azione protettiva sulla vista”
BR102017018080A2 (pt) * 2017-08-23 2019-03-19 Centro Federal De Educação Tecnológica De Minas Gerais Matrizes para a engenharia de tecidos na forma de espumas, fibras e/ou membranas constituídas por polímeros, cerâmicas, compósitos poliméricos e/ou compósitos cerâmicos contendo extrato de bixa orellana l. e o método de obtenção
JP2019104729A (ja) * 2017-12-11 2019-06-27 国立大学法人京都大学 網膜変性疾患抑制剤
FR3082122B1 (fr) * 2018-06-11 2021-01-01 Basf Beauty Care Solutions France Sas Utilisation d'un extrait de bixa orellana
FR3105790B1 (fr) * 2019-12-26 2022-01-14 Biophytis Composés chimiques ciblant l’œil et leur utilisation dans le traitement de maladies oculaires
US11759449B2 (en) 2021-11-02 2023-09-19 Hugg LLC Methods for reducing oxidative effects of free radicals

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8917323D0 (en) * 1989-07-28 1989-09-13 Inverni Della Beffa Spa Methods and pharmaceutical compositions for the treatment of ophthalmic diseases
US5731294A (en) * 1993-07-27 1998-03-24 Hybridon, Inc. Inhibition of neovasularization using VEGF-specific oligonucleotides
WO2001085183A2 (en) * 2000-05-08 2001-11-15 N.V. Nutricia Preparation for the prevention and treatment of ocular disorders
EP1633367A2 (en) * 2003-05-28 2006-03-15 EntreMed, Inc. Antiangiogenic agents
WO2005077176A1 (en) * 2004-02-11 2005-08-25 The Trustees Of Columbia University In The City Of New York Anthocyanin compounds and methods of use thereof
JP5223083B2 (ja) * 2006-06-21 2013-06-26 国立大学法人京都大学 血管新生抑制剤
CN101322743A (zh) * 2008-08-01 2008-12-17 李翔 一种能修复眼部病变损伤改善视力疲劳的制剂及其制备方法
US20110039796A1 (en) * 2009-04-17 2011-02-17 Zhijun Liu Natural Composition for Anti-Angiogenesis and Anti-Obesity
FR2947173B1 (fr) * 2009-06-25 2012-01-27 Inst Biophytis Composition alimentaire destinee a la protection solaire
JP2012036146A (ja) * 2010-08-10 2012-02-23 Oriza Yuka Kk 可視光誘発網膜障害抑制剤及びそれを用いた眼疾患予防・治療剤
JP2012062258A (ja) * 2010-09-14 2012-03-29 Oriza Yuka Kk 血管新生抑制剤及びそれを用いた眼疾患予防・治療剤
JP2012097003A (ja) * 2010-10-29 2012-05-24 Gifu City ビキシン誘導体及び細胞保護剤

Also Published As

Publication number Publication date
HUE031161T2 (en) 2017-07-28
FR2975008A1 (fr) 2012-11-16
PL2717891T3 (pl) 2017-04-28
US20140322371A1 (en) 2014-10-30
ES2609604T3 (es) 2017-04-21
JP6432913B2 (ja) 2018-12-05
FR2996773B1 (fr) 2016-08-05
EP2717891A1 (fr) 2014-04-16
JP6421306B2 (ja) 2018-11-14
FR2975008B1 (fr) 2014-03-07
WO2012156600A1 (fr) 2012-11-22
HRP20161718T1 (hr) 2017-02-24
US20170354638A1 (en) 2017-12-14
BR112013029318A2 (pt) 2017-04-18
JP2014514366A (ja) 2014-06-19
FR2996773A1 (fr) 2014-04-18
EP2717891B1 (fr) 2016-09-14
JP2017114892A (ja) 2017-06-29
PT2717891T (pt) 2016-12-29

Similar Documents

Publication Publication Date Title
DK2717891T3 (da) Bixa Orellana-sammensætning til behandling af makulær degeneration
Kijlstra et al. Lutein: more than just a filter for blue light
Froger et al. Taurine: the comeback of a neutraceutical in the prevention of retinal degenerations
Meagher et al. Serum response to supplemental macular carotenoids in subjects with and without age-related macular degeneration
Bisti et al. Saffron and retina: Neuroprotection and pharmacokinetics
KR20160140859A (ko) 당뇨성 안질환에 대한 친지질성 영양소의 효과
Peng et al. Influence/impact of lutein complex (marigold flower and wolfberry) on visual function with early age-related macular degeneration subjects: a randomized clinical trial
US20180042894A1 (en) Eye health composition
WO2017135466A1 (ja) キサントフィルとヒシ属植物の加工物を含有する組成物
Yang et al. Effect of astaxanthin on metabolic cataract in rats with type 1 diabetes mellitus
RU2715889C2 (ru) Композиция, содержащая норбиксин, для защиты клеток пигментного эпителия сетчатки
Chandrika et al. Carotenoid content and in vitro bioaccessibility of lutein in some leafy vegetables popular in Sri Lanka
Wang et al. The selective retention of lutein, meso-zeaxanthin and zeaxanthin in the retina of chicks fed a xanthophyll-free diet
JP6148780B1 (ja) キサントフィルとヒシ属植物の加工物を含有する組成物
Berendschot et al. Plant stanol and sterol esters and macular pigment optical density
Ozawa et al. Lutein and oxidative stress-mediated retinal neurodegeneration in diabetes
RU2659682C1 (ru) Средство на основе биологически активных соединений морских гидробионтов, обладающее канцерпревентивным действием и повышающее терапевтическую активность противоопухолевых антибиотиков
Rusli et al. Supplementation of mangosteen pericarp meal and vitamin E on egg quality and blood profile of laying hens
Srividya et al. Physical, chemical and biological properties of lutein: A Review
Otsu et al. Protective effect of Vaccinium myrtillus L. extract against UVA-induced injury in ARPE-19 cells
Alvarado et al. Egg Carotenoids and Eye Health
Ozawa et al. Diabetes: Chapter 23. Lutein and Oxidative Stress-Mediated Retinal Neurodegeneration in Diabetes
Sethna et al. Dietary Antioxidants, αvβ5 Integrin, and Ocular Protection: Long-Term Consequences of Arrhythmic Retinal Pigment Epithelium Phagocytosis
GENOTYPE EJO
Jung Natural Products and Retinal Ganglion Cells: Protective Roles of Edible Wild Vegetables Against Oxidative Stress in Retinal Ganglion Cells